SAR103168

Networked: 2 relevant articles (0 outcomes, 1 trials/studies)

1.	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 02/01/2015 - "Phase I trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndrome."
2.	Leukemia 02/01/2015 - "Phase I trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndrome."
3.	Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome) 07/01/2013 - "SAR103168 showed potent anti-tumor activity in SCID (severe combined immunodeficiency) mice bearing AML (KG1, EOL-1, Kasumi-1, CTV1) and chronic myeloid leukemia (CML) (K562) tumors. "
4.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 07/01/2013 - "SAR103168 inhibited the phosphorylation of STAT5 in KG1 cells and fresh cells from patients with acute myeloid leukemia (AML). "
5.	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 07/01/2013 - "SAR103168 showed potent anti-tumor activity in SCID (severe combined immunodeficiency) mice bearing AML (KG1, EOL-1, Kasumi-1, CTV1) and chronic myeloid leukemia (CML) (K562) tumors. "

1.	Phosphotransferases (Kinase)
2.	Cytarabine (Cytosar-U)
3.	Tyrosine Kinase Inhibitors

1.	Intravenous Administration